9
Participants
Start Date
June 29, 2022
Primary Completion Date
March 14, 2024
Study Completion Date
March 14, 2024
Allocetra-OTS
Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.
The Chaim Sheba Medical Center, Ramat Gan
Lead Sponsor
Enlivex Therapeutics RDO Ltd.
INDUSTRY